Collaborations and business development are integral to our growth strategy and have played a key role in our complex generics and biosimilars business.
Momenta has two major complex generic collaborations with Sandoz, a division of Novartis.
In January 2016, Momenta entered into a broad global collaboration with Mylan for the development, manufacture and commercialization of six of Momenta’s biosimilar candidates, including M834, Momenta's ORENCIA® (abatacept) biosimilar candidate.
Momenta is currently pursuing development or commercial stage collaborations in the following areas:
If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at email@example.com.
LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa® is a trademark of Novartis AG.
Last Updated 1/4/2017